Moreover, we show that the effect of SERPINB3 loss on radiation sensitivity in cervical tumor cells is similar if not greater than cisplatin, currently used as the standard of care to radiosensitize cervical cancer. This evidence concerns the gene SERPINB3 and uterine cervix neoplasm.